Psoriasis: Ustekinumab and Other Biologics in the Pipeline

The improved understanding of the complex immunology and pathogenesis of psoriasis and psoriatic arthritis has established the therapeutic utility of targeted biologic therapies against the pathogenic T cells and the inflammatory cytokines. Particular interest in the interleukin (IL)-23/T helper (Th) 17 pathway has led to the development of ustekinumab, which is now approved and widely marketed for the treatment of psoriasis, as well as various investigational biologic agents in current clinical trials. Lack of or improper treatment of psoriasis and psoriatic arthritis can inevitably result in considerable morbidity and quality of life issues for affected patients, emphasizing the continued need for drug research and development to achieve optimal management.